UFOX + Cetuximab + FOLFOX4 + Cetuximab
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Previously Untreated Metastatic Colorectal Cancer
Conditions
Previously Untreated Metastatic Colorectal Cancer
Trial Timeline
Feb 1, 2007 → May 1, 2012
NCT ID
NCT00439517About UFOX + Cetuximab + FOLFOX4 + Cetuximab
UFOX + Cetuximab + FOLFOX4 + Cetuximab is a phase 2 stage product being developed by Merck for Previously Untreated Metastatic Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00439517. Target conditions include Previously Untreated Metastatic Colorectal Cancer.
What happened to similar drugs?
1 of 3 similar drugs in Previously Untreated Metastatic Colorectal Cancer were approved
Approved (1) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00439517 | Phase 2 | Completed |
Competing Products
8 competing products in Previously Untreated Metastatic Colorectal Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR-A1811 + Pyrotinib in combination with Capecitabine. + SHR-A1811 | Jiangsu Hengrui Medicine | Phase 3 | 44 |
| AZD1775 + AZD1775 Placebo + Antimitotic Agent + pegfiligrastim | AstraZeneca | Phase 2 | 27 |
| AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatin | AstraZeneca | Phase 2 | 27 |
| Idelalisib + Nab-paclitaxel + mFOLFOX6 | Gilead Sciences | Phase 1 | 21 |
| Bosutinib | Pfizer | Approved | 35 |
| CRS-207 + CRS-207 + nivolumab + GVAX + CY | Bristol Myers Squibb | Phase 2 | 35 |
| Lenalidomide + Dexamethasone + Elotuzumab | Bristol Myers Squibb | Phase 3 | 32 |
| Oxaliplatin | Sanofi | Phase 2 | 31 |